Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

CIP2A confirms its prognostic value in triple-negative breast cancer

Oncogene volume 36, pages 3357–3358 (2017)Cite this article

Subjects

Deregulation of the cancerous inhibitor of protein phosphatase 2A (CIP2A) has been reported to contribute to breast cancer progression. Of importance, the triple-negative subtype (TNBC) includes those breast cancer cases with worst prognosis and therapeutic options. We confirm here recent findings suggesting that CIP2A is frequently upregulated and defines a subgroup of TNBC patients with very poor prognosis. Our findings further support CIP2A as a novel promising molecular target for breast cancer patients with triple-negative subtype.

We have read the recently published manuscript by Liu et al.,1 which provides novel relevant findings about the functional and clinical significance of CIP2A in triple-negative breast cancer (TNBC). In this work, the authors demonstrated that CIP2A promotes both cell cycle progression and tumor growth through regulating the PP2A/c-myc/p27Kip1-signaling axis using in vitro and in vivo models of this disease. Moreover, they showed that high CIP2A expression associates with the triple-negative subtype and predicts shorter overall survival (OS) in TNBC. Despite these observations are of high importance, one limitation of this study is that they only included 52 TNBC patients. Therefore, further confirmation of the clinical relevance of CIP2A in independent TNBC cohorts is warranted.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Liu H, Qiu H, Song Y, Liu Y, Wang H, Lu M et al. Cip2a promotes cell cycle progression in triple-negative breast cancer cells by regulating the expression and nuclear export of p27Kip1. Oncogene 2016,; e-pub ahead of print 3 October 2016 doi:10.1038/onc.2016.355.

    Article  Google Scholar 

  2. Come C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X et al. CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res 2009; 15: 5092–5100.

    Article  CAS  Google Scholar 

  3. Laine A, Sihto H, Come C, Rosenfeldt MT, Zwolinska A, Niemela M et al. Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. Cancer Discov 2013; 3: 182–197.

    Article  CAS  Google Scholar 

  4. Rincón R, Cristóbal I, Zazo S, Arpí O, Menéndez S, Manso R et al. PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects. Oncotarget 2015; 6: 4299–4314.

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported by PT13/0010/0012, PI13/02609 and PI15/00934 grants from ‘Instituto de Salud Carlos III FEDER’. BT is supported by ‘Fundación Conchita Rábago de Jiménez Díaz’.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Translational Oncology Division, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital ‘Fundacion Jimenez Diaz’, Madrid, Spain

    I Cristóbal, B Torrejón, M Pedregal & J García-Foncillas

  2. Department of Pathology, IIS ‘Fundación Jiménez Diaz’, Madrid, Spain

    S Zazo, J Madoz-Gúrpide & F Rojo

  3. Department of Medical Oncology, Hospital del Mar, Barcelona, Spain

    A Rovira & J Albanell

  4. Department of Breast Cancer Research, Institute of Health Research INCLIVA, Valencia, Spain

    A Lluch & P Eroles

Authors
  1. I Cristóbal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Zazo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B Torrejón
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Pedregal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Madoz-Gúrpide
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Lluch
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P Eroles
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A Rovira
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J Albanell
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J García-Foncillas
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. F Rojo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to I Cristóbal or F Rojo.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Oncogene website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cristóbal, I., Zazo, S., Torrejón, B. et al. CIP2A confirms its prognostic value in triple-negative breast cancer. Oncogene 36, 3357–3358 (2017). https://doi.org/10.1038/onc.2016.474

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2016.474

This article is cited by

Search

Advanced search

Quick links